Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review
Last updated Apr 2, 2026 by RSS Ingestion
Details
Two major biopharmaceutical media accounts currently handled by Omnicom—Bristol Myers Squibb and Gilead Sciences—are in review or set to go into review.